BIOJECT REPORTS UNAUDITED SECOND QUARTER 2015 FINANCIAL RESULTS
Tigard, OR – August 14, 2015 – Bioject Medical Technologies Inc. (OTC Pink: BJCT), a developer and
manufacturer of needle-free injection therapy systems, today reported unaudited financial results for the
second quarter ended June 30, 2015. The financial results are unaudited and actual results may vary.
Bioject reported revenues of $215,000 for the quarter ended June 30, 2015, compared to revenues of
$513,000 in the comparable 2014 period. Operating expense was $392,000 for the second quarter of 2015,
compared to $788,000 in the second quarter 2014. The Company reported an operating loss of $177,000 in
the second quarter of 2015, compared to an operating loss of $275,000 in the second quarter of 2014. Net
loss allocable to common shareholders for the second quarter of 2015 was $276,000, compared to $331,000
in the comparable 2014 period.
Basic and diluted net loss per share allocable to common shareholders for the quarter ended June 30, 2015
was $0.01 per share on 39.1 million weighted average shares outstanding compared to a basic and diluted
net loss of $0.01 per share on 32.4 million weighted average shares outstanding for the same period in 2014.
For the six months ended June 30, 2015, Bioject reported revenues of $529,000, compared to revenues of
$855,000 in the comparable period of 2014. Operating expense was $959,000 for the six-month period of
2015, compared to $1.4 million for the comparable period of 2014. The Company reported an operating loss
of $430,000 for the six-month period of 2015, compared to $534,000 in the comparable period of 2014. Net
loss allocable to common shareholders was $603,000, or $0.02 per basic and diluted share on 39.0 million
weighted average shares outstanding in the six-month period ended June 30, 2015 compared to $647,000, or
$0.03 per basic and diluted share on 25.7 million weighted average shares outstanding in the comparable
period of 2014.
Bioject Medical Technologies Inc., based in Tigard, Oregon, USA, is a developer and manufacturer of
needle-free injection therapy systems (NFITS). NFITS works by forcing medication at high speed through a
tiny orifice held against the skin. This creates a fine stream of high-pressure fluid penetrating the skin and
depositing medication in the tissue beneath. Bioject is focused on developing mutually beneficial
agreements with leading pharmaceutical, biotechnology, and veterinary companies, as well as research,
global health and government organizations.
